Newswire (Published: Tuesday, September 26, 2017, Received: Thursday, September 21, 2017, 11:13:13 PM CDT)

Word Count: 518

Recent Findings in Prostate Cancer Described by Researchers from University of Michigan (Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, "New cancer biomarkers are being discovered at a rapid pace; however, these tests vary in their predictive performance characteristics, and it is unclear how best to use them. We investigated 2-stage biomarker-based screening strategies in the context of prostate cancer using a partially observable Markov model to simulate patients' progression through prostate cancer states to mortality from prostate cancer or other causes."

Financial supporters for this research include Early Detection Research Network, National Science Foundation, University of Michigan MCubed program (see also Oncology - Prostate Cancer).

Our news editors obtained a quote from the research from the University of Michigan, "Patients were screened every 2 years from ages 55 to 69. If the patient's serum prostate-specific antigen (PSA) was over a specified threshold in the first stage, a second stage biomarker test was administered. We evaluated design characteristics for these 2-stage strategies using 7 newly discovered biomarkers as examples. Monte Carlo simulation was used to estimate the number of screening biopsies, prostate cancer deaths, and quality-adjusted life-years (QALYs) per 1000 men. The all-cancer biomarkers significantly underperformed the high-grade cancer biomarkers in terms of QALYs. The screening strategy that used a PSA threshold of 2 ng/mL and a second biomarker test with high-grade sensitivity and specificity of 0.86 and 0.62, respectively, maximized QALYs. This strategy resulted in a prostate cancer death rate within 1% of using PSA alone with a threshold of 2 ng/mL, while reducing the number of biopsies by 20%. Sensitivity analysis suggests that the results are robust with respect to variation in model parameters."

According to the news editors, the research concluded: "Two-stage biomarker screening strategies using new biomarkers with risk thresholds optimized for high-grade cancer detection may increase quality-adjusted survival and reduce unnecessary biopsies."

For more information on this research see: Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. Medical Decision Making, 2017;37(7):815-826. Medical Decision Making can be contacted at: Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA. (Sage Publications -; Medical Decision Making -

The news editors report that additional information may be obtained by contacting B.T. Denton, University of Michigan, Dept. of Urol, Ann Arbor, MI 48109, United States. Additional authors for this research include S.A. Tomlins, D.J. Underwood, J.T. Wei, T.M. Morgan, J.E. Montie and C.L. Barnett.

Keywords for this news article include: Ann Arbor, Michigan, United States, North and Central America, Cancer, Diagnostics and Screening, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Prostate Cancer, Oncology, University of Michigan.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


University of Michigan
National Science Foundation
Sage Publications Inc.


Central America
North America
United States
Thousand Oaks
Ann Arbor


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer